Douglas Flora: Why now is the time to start investing in AI education
Douglas Flora, Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, shared a post on LinkedIn, about a paper by Ethan Goh et al. published in JAMA Network Open.
“Sharing a new and compelling study published in JAMA Network Open that underscores why now is the time to start investing in AI education.
These AI systems have shown the potential to:
- Reduce administrative burdens
- Assist with clinical decision-making
- Improve patient communication
For healthcare professionals, the ability to use AI effectively hinges on understanding how to engage with it—what we call ‘prompt engineering’. This skill mirrors the art of asking precise, structured questions in clinical practice. The better we are at defining the problem, the better the answers AI can provide.
Some might argue that this is a passing trend or that AI isn’t ready for healthcare. But the data in this study paints a different picture. LLMs are already being integrated into workflows, saving time, improving accuracy, and even identifying insights that might otherwise be missed.
As the technology advances, the real question is: Will you be ready to use it?
Education is the first step. Whether it’s learning how to craft effective prompts, understanding AI’s limitations, or exploring how it can enhance your specific clinical practice, investing time in AI education now isn’t optional—it’s essential.
What’s holding you back from diving into AI in healthcare?”
Authors: Ethan Goh, Robert Gallo,Jason Hom, Andrew Olson, Adam Rodman,Jonathan Chen et al.
More posts featuring Douglas Flora.
Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, overseeing clinical operations, strategic planning, and the expansion of cancer programs. He is also the co-founder of the Center for Precision Medicine; Genomic Health.
As the Editor-in-Chief of ‘AI in Precision Oncology,’ the first peer-reviewed academic journal dedicated to this field, he plays a pivotal role in advancing research. He is also an active board member of the American Cancer Society and ACCC, where he contributes to advocacy, education, and innovation within the cancer community.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023